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Background: Rapidly increasing prevalence of diabetes throughout the world highlights the importance of looking
for new treatment options for the disease such as stem cell therapy. With regard to the increasing attention towards
stem-cell therapy as a curative treatment for diabetes in recent years, it is of crucial importance to ensure the safety of
this novel therapeutic technique. In this study we aim to evaluate the safety of fetal liver-derived cell suspension
allotransplantation in the diabetic patients who had attended a clinical trial in 2007.
Methods: 44 out of a total number of 56 patients who had undergone either fetal liver-derived cell suspension
allotransplantation or placebo injection in 2007 (IRCT number: 138811071414 N10) were contacted and recruited
for the evaluation of possible complications. Patients were referred to a designated ophthalmologist and cardiologist to
be screened for retinopathy and cardiovascular diseases. 24-hour urine was collected and tested for the evaluation of
nephropathy; and, neuropathy was assessed by means of neuropathic symptoms and monofilament test.
Results: There were no life-threatening complications nor significant differences in terms of evaluated diabetes
complications ( retinopathy, neuropathy, nephropathy and cardiovascular diseases ) between the case and control
groups. However, one case of meningioma was reported.
Conclusions: Findings of our study demonstrated that stem cell transplantation can be considered a relatively
safe procedure apart from one case of meningioma; it did neither cause any life-threatening complications nor
increased the rate of the diabetes micro- and macrovascular complications.
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Type 1 diabetes mellitus (T1DM) is demonstrated to be
caused by an autoimmune mechanism which leads to
destruction of β-cells in the pancreas [1]. Similarly, it is
hypothesized that in type 2 diabetes mellitus (T2DM), β
cells undergo apoptosis via some obscure immunological
mechanisms. In both types of diabetes, the disease pro-
gress is towards reducing the number of islet cells due
to immunological interactions [1-7] . Therefore, many
novel therapeutic options have been developed for treat-
ment of diabetes in recent years that focused on combining* Correspondence: emrc@tums.ac.ir
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cell function [8].
Islet-cell transplantation and whole pancreas trans-
plantation are considered as curative treatment options
although their clinical benefits are limited. Scarcity of
donors and the side effects of immunosuppressive drugs
which are usually indicated after the transplantation can
be considered as major limitations of these procedures.
Therefore, there is a need to develop new therapeutic
approaches for the treatment of diabetes such as stem-
cell therapy as well as investigating their long-term
safety [9-11]. Considering the novelty of the new
approaches, there are limited data regarding their po-
tential risks and complications. Therefore, it is of cru-
cial importance to evaluate the long-term safety of such
new therapeutic approaches.cess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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there are still serious concerns remaining over the safety
of this novel treatment [12]. In two different studies, two
cases of benign tumors in the nervous system and the
kidney are reported following stem-cell transplantation
[13,14]. As stem-cell therapy is not widely applied and
considering the novelty of the technique which makes
it impossible to conduct extensive follow up studies
[13,14], we aimed to conduct a 3-year safety follow-up
of patients with diabetes who had undergone fetal liver-
derived cell suspension allotransplantation in a study
done by Ghodsi et al. in 2007 [15].
Matherial and methods
56 patients with type one (n = 30) and type 2 (n = 26) dia-
betes who had previously participated in a double blind
randomized controlled clinical trial in 2007 (Ethical
Code: 0089 and IRCT number: 138811071414 N10), had
been visited at the 6th and the 12th months after
injection. Briefly, fetal liver-derived hematopoietic stem
cells (HSCs) were isolated from legally and aborted hu-
man fetuses aged 6–12 weeks after obtaining an
informed consent from the parents (mother or both of
the parents). In order to determine chromosomal abnor-
malities and to identify the sex of the donated fetus,
karyotyping was done for each fetal sample. Whole fetal
liver was placed in Hank’s balanced salt solution without
calcium and magnesium (HBSS, Sigma, USA) and disso-
ciated and homogenized mechanically. The cell suspen-
sion was filtered through nylon mesh to undergo
transplantation; and then, isolated cells were cryopre-
served using 5% dimethyl sulfoxide (DMSO) in HBSS,
(Wak Chemie, Germany) with a programmable freezer,
and were transferred to liquid nitrogen for long term
storage. Before transplantation, samples were thawed at
37oC and cryoprotectant was diluted by 5 milliliter nor-
mal saline before infusion. Total cell count in the pre-
pared suspension was approximately 35-55 × 106, twenty
percent of which was recognized as hematopoietic
(CD34+) stem cells. The suspension was checked before,
during, and after processing for aerobic, anaerobic and
fungal contamination as well as viral infections. Rubella,
Herpes Simplex Virus, Cytomegalovirus, Chlamydia,
Mycoplasma Homonis, Toxoplasma Gondii and Trepo-
nema Pallidume were checked using ELISA (enzyme
linked immunoassay). DNA/RNA extraction and poly-
merase chain reaction (real-time PCR) were done for
checking viral contamination (HBV, HCV, and HIV).
After evaluating the results, cell samples were known
qualified for the transplantation. Injectable normal saline
at the dosage of 5 ml was considered as the placebo solu-
tion. On the day of transplantation each participant in
the intervention group received fetal liver-derived cell
suspension at the dosage of approximately 35-55 × 106cells (7-11 × 106 CD34+ HSCs) in 5 milliliter of normal
saline intravenously. Participants in placebo group re-
ceived 5 milliliter of normal saline intravenously [15].
Three years after the transplantation in 2009, the pa-
tients who were available through mailing address or
telephone numbers were contacted and visited over a
3-months period. 44/56 signed an informed consent
and agreed to participate in the current study. Unfortu-
nately, 12/56 patients were not available at the address
or telephone numbers they had given at the time of
transplantation in 2007.
Patients were referred to the same ophthalmologist for
the assessment of diabetes retinopathy, and similar to the
previous visits [15], the results were reported as normal,
Non–Proliferative Diabetic Retinopathy (NPDR), and
Proliferative Diabetic Retinopathy (PDR). Peripheral arter-
ies were examined through Posterior Tibialis and Dorsalis
Pedis pulses . Similar to the previous study [15], neuropathy
was defined by related symptoms complained by the pa-
tients. The same method was used for the assessment of
neuropathy: patients were examined with 10-g monofila-
ments and the results were reported as presence or absence
of neuropathy [16]. EMG and NCV were not performed. In
our study, neuropathy was defined as burning pain, elec-
trical or stabbing sensations, parasthesia, hyperesthesia,
deep aching pain and the loss of 10-gmonofilament percep-
tion at the distal halluces [16].
As for the assessment for nephropathy, 24-hours urine
was collected and tested for proteinuria and the results
were reported as no albuminuria, micro-albuminuria
and macro-albuminuria [17,18]. For evaluating the car-
diovascular complications, patients were referred to the
same cardiologist. In addition to a complete history
taking and thorough physical examination, ECG was
performed in all patients and if necessary, exercise stress
test and angiography were requested; and, the results
were reported by the cardiologist as normal or Ischemic
Heart Disease (IHD). History of myocardial infarction,
unstable angina, positive exercise tolerance test, angio-
graphic evidence of arterial stenosis, ECG abnormalities
or the history of Coronary Artery Bypass Graft (CABG)
were defined as IHD[19,20]. In addition, HbA1c levels
had been measured to evaluate the glycemic control in
these patients. All examiners were blinded in this study.
Statistical analysis was performed with the use of SPSS
software (version: 17.0) and significance level was set at
0.05. Independent t-test and Chi square test (Fisher’s
exact test) was used to compare complications between
the intervention and placebo groups before and 3 years
after transplantation.
Results
In the 3rd year of follow-up in 2009, 44 of 56 patients
who had undergone fetal liver-derived cell suspension
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visited for the assessment of the course of their disease
or any other potential life-threatening complications of
the transplantation. The 12 missing patients whom we
failed to follow because of the change in their contact
phone number or mailing address consisted of both the
intervention (one patient with T1DM and three patients
with T2DM) and the placebo group (five patients with
T1DM and three patients with T2DM) . The demo-
graphic data and HbA1c levels of all patients were
recorded both at the baseline and 3 years post trans-
plantation. The demographic data and HbA1c levels of
those who were missed over the follow-up period were
similar to that of those who could attend this study both
in the intervention and placebo groups (Table 1).
In both type one and two diabetic patients, results of
the clinical investigations three years after the proced-
ure clearly revealed that there were no significant dif-
ferences in the incidence or progression of diabetes
micro vascular complications in patients who had
either undergone fetal liver-derived cell suspension
allotransplantation or received placebo compared to the
baseline (Table 2).
None of the patients with type 1 diabetes had cardio-
vascular complications, neither at the baseline nor after
3 years. For patients with type 2 diabetes, our findings
showed that there was no statistically significant differ-
ence in terms of cardiovascular complications incidence
in the intervention and placebo group after three years
(Table 3).
However, the most important finding in the follow-up
visits was the point that we found one patient who had
developed meningioma probably with the origin of trans-
planted cells. This case is presented and discussed indi-
vidually in another article.Table 1 Baseline demographic characteristics and HbA1c levels
Variable
Intervention (N = 28) Age (mean ± std)
Female % (n)
Duration of diabetes(mean ± std)
HbA1c(%) at baseline
HbA1c(%) at 1 year F.U
variable
Placebo (N = 28) Age (mean ± std)
Female % (n)
Duration of diabetes(mean ± std)
HbA1c(%) at baseline
HbA1c(%) at 1 year F.U
aindependent t-test.Discussion
Evaluating the safety of stem cell transplantation for
treatment of diabetes, our results demonstrated that
fetal liver-derived cell suspension allotransplantation
did not lead to any life-threatening complications in
the patients attending the follow-up visits three years
after the transplantation in the three-year follow-up
period. In addition, we observed no improvement or
progress in diabetes micro- and macrovascular compli-
cations(retinopathy, neuropathy, and nephropathy and
IHD) in the transplantation group compared with the
placebo group as well as no new cases of the mentioned
complications (Tables 2 and 3). Since the patients had
received intensive diabetes care over the three years
after the transplantation, it is hard to conclude that ob-
serving no progression in the noted diabetes complica-
tions was attributed whether to the cell therapy or
resulted from diabetes care.
However, we noticed a case of meningioma in the
transplantation group which will be discussed in detail
in another article. Briefly, A 57-year-old female patient
with type 1 diabetes who had undergone fetal liver-
derived cell suspension allotransplantation, attended the
clinic with the history of progressive bi-frontal head-
aches accompanied by nausea, vomiting, and visual
disturbances over the past 8 months. Investigations re-
vealed a 2-cm mass in the right temporal region. Thus,
the patient underwent craniotomy and the lesion was
removed and sent for pathological and genetic investiga-
tions. The results were suggestive of “Transitional Men-
ingioma” with the origin of transplanted fetal hematopoietic
stem cells.
In contrast to our results, different complications of stem-
cell therapy are reported in several studies [13,14,21,22].
Voltarelli et al. reported one case of culture-negative bilateralof the missing pati in the intervention and placebo groups
Not missed Missing group p-valuea
34.95 ± 17.09 41.75 ± 15.88 0.465
14/24(58.3%) 4/4(100%) 0.107
5.10 ± 2.62 5.75 ± 2.06 0.645
9.90 ± 1.79 11.30 ± 2.66 0.19
8.76 ± 1.81 9.00 ± 2.70 0.825
Not Missed Missing Group p-valuea
(N = 20) (N = 8)
32.00 ± 14.09 24.25 ± 18.34 0.239
11/20(55.0%) 5/8(62.5%) 0.717
5.47 ± 3.04 3.37 ± 2.98 0.109
9.78 ± 1.63 9.86 ± 0.96 0.895
8.31 ± 2.09 9.45 ± 2.32 0.253
Table 2 Presence of retinopathy,neuropathy and microalbuminuria in patients with type 1 diabetes at the baseline
and 3 years following the intervention
Type 1 diabetes Retinopathy (baseline) Total P-Value Rethinopathy (3rd year) Total P-Value
Normal PDR Normal NPDR
Groups Intervention Count 13 0 13 0.999b 11 1 12 0.999b
(%) 100.0% .0% 100.0% 91.7% 8.3% 100.0%
Placebo Count 16 1 17 12 0 12
(%) 94.1% 5.9% 100.0% 100.0% .0% 100.0%
Total Count 29 1 30 23 1 24
(%) 96.7% 3.3% 100.0% 95.8% 4.2% 100.0%
Neuropathy (Basal) Total P-Value Neuropathy (3rd year) Total P-Value
no_neurophathy neuropathy+ no_neurophathy neuropathy+
Groups Intervention Count 12 1 13 0.433b 10 2 12 0.478b
(%) 92.3% 7.7% 100.0% 83.3% 16.7% 100.0%
Placebo Count 17 0 17 12 0 12
(%) 100.0% .0% 100.0% 100.0% .0% 100.0%
Total Count 29 1 30 22 2 24
(%) 96.7% 3.3% 100.0% 91.7% 8.3% 100.0%
Microalbominuria (baseline) Total P-Value Microalbominuria (3rd year) Total P-Value
No Albominuria Microalbominuria+ No Albominuria Microalbominuria+
Groups intervention Count 12 1 13 0.844a 12 0 12 0.307a
(%) 92.3% 7.7% 100.0% 100.0% .0% 100.0%
placebo Count 16 1 17 11 1 12
(%) 94.1% 5.9% 100.0% 91.7% 8.3% 100.0%
Total Count 28 2 30 23 1 24
(%) 93.3% 6.7% 100.0% 95.8% 4.2% 100.0%
aPearson Chi-Square.
bFisher’s Exact Test.
*Pearson Chi-Square is not computed because IHD (3rd year) is a constant.
PDR:Proliferative Diabetic Retinopathy, NPDR:None Proliferative Diabetic Retinopathy.
neuropathy+ : having neuropathy.
Microalbominuria+: 30 ≤ urine albominuria <300 (ng/mL).
IHD+: having Ischemic Heart Disease.
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function (hypothyroidism and hypogonadism) following
autologous nonmyeloablative hematopoietic stem-cell
transplantation in newly diagnosed type 1 diabetic pa-
tients [21,23]. However, it is still difficult to conclude
that these complications developed as a result of stem
cell transplantation only. Thus, the role of immunosup-
pressive drugs used in these studies should also be
taken into consideration. We used fetal liver-derived
stem-cells, which unlike hematopoietic stem-cells, do
not need administration of cytotoxic drugs because of
their low immunogenicity along with high self-renewal
capacity [24]. Moreover, in a study by Amariglio et al.,
brain and spinal cord tumors were reported in a patient
with ataxia telangiectasia who had undergone human
fetal neural stem-cell transplantation [13]. However,
these complications might be due to the direct injection
of the cells into the target organ [13,14]. It is also suggestedthat complications observed in the study by Amariglio et al.
are because of the increased susceptibility of developing tu-
mors in patients with ataxia telangectasia which might be
evenmore exaggerated after the injection of stem-cells [25].
Another case is reported in Taiwan in a patient with lupus
nephritis who had undergone local renal injection of au-
tologous hematopoietic stem cells collected from periph-
eral blood and mobilized by G-CSF. After the procedure,
angiomyeloproliferative lesions were developed in the left
kidney as well as smaller lesions in the right Adrenal gland
and the liver. Similarly, it may be suggested that the tumors
could have been developed due to the direct blind injection
of stem cells into the kidney [13].
There were several limitations to our investigation. The
most important one was the fact that we lost contact with
some patients in the third year of follow-up because of the
change in their addresses or phone numbers. Among the
missing group (n = 12), 8 patients were in the placebo
Table 3 Presence of retinopathy, neuropathy, microalbuminuria, and Ischemic Heart Disease(IHD) in patients with type
2 diabetes at the baseline and 3 years after the intervention
Type 2 diabetes Retinopathy (baseline) Total P-Value Rethinopathy (3rd year) Total P-Value
Normal PDR Normal NPDR
Groups Intervention Count 13 2 15 0.373a 12 0 12 0.400b
(%) 86.7% 13.3% 100.0% 100.0% .0% 100.0%
Placebo Count 8 3 11 7 1 8
(%) 72.7% 27.3% 100.0% 87.5% 12.5% 100.0%
Total Count 21 5 26 19 1 20
(%) 80.8% 19.2% 100.0% 95.0% 5.0% 100.0%
Neuropathy (Basal) Total P-Value Neuropathy (3rd year) Total P-Value
no_neurophathy neuropathy+ no_neurophathy neuropathy+
Groups Intervention Count 8 7 15 0.315a 8 4 12 0.292a
(%) 53.3% 46.7% 100.0% 66.7% 33.3% 100.0%
Placebo Count 8 3 11 7 1 8
(%) 72.7% 27.3% 100.0% 87.5% 12.5% 100.0%
Total Count 16 10 26 15 5 20
(%) 61.5% 38.5% 100.0% 75.0% 25.0% 100.0%
Microalbominuria (baseline) Total P-Value Microalbominuria (3rd year) Total P-Value
No Albominuria Microalbominuria+ No Albominuria Microalbominuria+
Groups intervention Count 14 1 15 0.364a 11 1 12 0.999b
(%) 93.3% 6.7% 100.0% 91.7% 8.3% 100.0%
placebo Count 9 2 11 8 0 8
(%) 81.8% 18.2% 100.0% 100.0% .0% 100.0%
Total Count 23 3 26 19 1 20
(%) 88.5% 11.5% 100.0% 95.0% 5.0% 100.0%
IHD (baseline) Total P-Value IHD (3rd year) Total P-Value
Normal IHD + Normal IHD +
Groups intervention Count 14 1 15 0.364a 9 3 12 0.494a
(%) 93.3% 6.7% 100.0% 75.0% 25.0% 100.0%
placebo Count 9 2 11 7 1 8
(%) 81.8% 18.2% 100.0% 87.5% 12.5% 100.0%
Total Count 23 3 26 16 4 20
(%) 88.5% 11.5% 100.0% 80.0% 20.0% 100.0%
aPearson Chi-Square.
bFisher’s Exact Test.
PDR:Proliferative Diabetic Retinopathy, NPDR:None Proliferative Diabetic Retinopathy.
neuropathy+: having neuropathy.
Microalbominuria+: 30 ≤ urine albominuria <300 (ng/mL).
IHD+: having Ischemic Heart Disease.
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patient with type 1 diabetes) were in the transplantation
group (Table 1). Therefore, it can be concluded from
these data that the missing group might not have any sig-
nificant impact on the final results of this study which
aims to report the potential complications of stem cell
transplantation for treatment of diabetes mellitus. More-
over, in terms of patient assessments, the methods
through which the complications had been evaluated,should have been more accurate in preclinical assess-
ments. Since the primary evaluations in 2007 had been
mainly reported qualitatively rather than using quantita-
tive scales, we had to use the same methods after 3 years
in our follow up visits. In addition, as the major objective
of this study was the evaluation of the incidence of malig-
nancy following fetal HSCs transplantation, we did not
use gold standard tests for the assessment of diabetes
complications. Moreover, not all body systems have been
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cations that is because such assessments were not per-
formed at baseline, or their gold standard tests were
invasive and costly. Therefore, we focused on the history
and the symptoms expressed by the patients.
Conclusion
To our knowledge, this is the first study that investi-
gated the incidence of tumors and several other compli-
cations following fetal liver-derived cell suspension
allotransplantation for the treatment of diabetes. The
results of our study indicated that fetal stem cell trans-
plantation did not cause any life-threatening complica-
tions as far as we observed and did not have any adverse
effects on diabetes related complications. Taking the limi-
tations of this study into consideration, it is still hard to
express that observing no progression in diabetes compli-
cations is whether attributed to fetal stem cell transplant-
ation or to the quality of diabetes care. Moreover, to
definitely conclude that transplantation of fetal stem cells
does not lead to any life-threatening events necessitates
further studies with longer follow-up periods and more
precise assessments using gold standard modalities in
order to evaluate the safety and efficacy of this novel treat-
ment option.
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